Ken Griffin Cti Biopharma Corp Transaction History

Citadel Advisors LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.2 - $6.01 $200,125 - $286,370	-47,649 Reduced 92.86%	3,662 $15,000
Q4 2022 Feb 14, 2023	SELL	$4.45 - $6.17 $1.96 Million - $2.71 Million	-439,486 Reduced 89.55%	51,311 $308,000
Q3 2022 Nov 14, 2022	SELL	$5.36 - $7.43 $1.76 Million - $2.44 Million	-328,777 Reduced 40.12%	490,797 $2.86 Million
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $2.55 Million - $4.5 Million	717,668 Added 704.25%	819,574 $4.89 Million
Q1 2022 May 16, 2022	BUY	$1.9 - $5.23 $151,601 - $417,301	79,790 Added 360.78%	101,906 $476,000
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.86 $68,482 - $136,013	-47,557 Reduced 68.26%	22,116 $54,000
Q3 2021 Nov 15, 2021	SELL	$2.25 - $3.18 $318,449 - $450,074	-141,533 Reduced 67.01%	69,673 $205,000
Q1 2021 May 17, 2021	BUY	$2.68 - $3.8 $506,962 - $718,827	189,165 Added 858.24%	211,206 $615,000
Q4 2020 Feb 16, 2021	BUY	$2.48 - $3.8 $54,661 - $83,755	22,041 New	22,041 $71,000
Q2 2020 Aug 14, 2020	SELL	$0.88 - $1.32 $25,774 - $38,661	-29,289 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$0.69 - $1.54 $31,123 - $69,463	-45,106 Reduced 60.63%	29,289 $27,000
Q4 2018 Feb 14, 2019	BUY	$0.73 - $2.19 $21,991 - $65,975	30,126 Added 68.05%	74,395 $54,000
Q3 2018 Nov 13, 2018	BUY	$1.72 - $5.24 $31,801 - $96,882	18,489 Added 71.72%	44,269 $0
Q2 2018 Aug 10, 2018	BUY	$3.81 - $5.26 $98,221 - $135,602	25,780 New	25,780 $0
Q1 2018 May 11, 2018	SELL	$2.7 - $4.06 $30,828 - $46,357	-11,418 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$2.47 - $3.34 $28,202 - $38,136	11,418	11,418 $31,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.